
Omid Hamid, M.D.
Dr. Omid Hamid is one of the oncology and hematology specialists who are currently affiliated with Cedars-Sinai Marina del Rey Hospital. He received his medical degree from the University of Southern California Keck School of Medicine and completed his residency at the Los Angeles County Hospital and University of Southern California Medical Center. Dr. Omid Hamid is recognized nationally and internationally as a key opinion leader in immuno-oncologic drug development and melanoma therapeutics. By virtue of his role as Chief of Immunotherapy and Translational Research, numerous patients have benefited from innovative, effective, paradigm-shifting drugs.
The physician was a key investigator in the initial clinical trials with Ipilimumab, Pembrolizumab, Nivolumab, Atazolizumab, and Vemurafenib, agents that led to considerable survival benefits in the lives of patients. The medical expert has offered his opinion in numerous articles in the online publication OncLive. Dr. Omid Hamid has presented his research at major national and international meetings, including the American Society of Clinical Oncology and the Society for Melanoma Research. He has published manuscripts, abstracts, and reviews on immunotherapy, targeted therapy, and melanoma care in prestigious journals such as the Journal of Clinical Oncology, the New England Journal of Medicine, and Clinical Cancer Research.
Insurance Accepted
- Aetna Choice POS II
- Cigna
- Great West PPO
- First Health PPO
- Multiplan PPO
Languages Spoken
- English
- Farsi
- Spanish
Education & Training

Medical Degree
University of Southern California Keck School of Medicine

Internship(s)
University of Southern California Medical Center

Residency(ies)
University of Southern California - LAC+USC Medical Center

Fellowship(s)
University of Southern California - LAC+USC Medical Center
Publications & Media
-
An immune-active tumor microenvironment favors clinical response to ipilimumab.
Ji, R., Chasalow, S.D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J., Alaparthy, S., Berman, D., Jure-Kunkel, M., Siemers, N.O., Jackson, J.R., Shahabi, V.
-
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
Massard, C., Gordon, M.S., Sharma, S., Rafii, S., Wainberg, Z.A., Luke, J., Curiel, T.J., Colon-Otero, G., Hamid, O., Sanborn, R.E., O'Donnell, P.H., Drakaki, A., Tan, W., Kurland, J.F., Rebelatto, M.C., Jin, X., Blake-Haskins, J.A., Gupta, A., Segal, N.H.
-
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
Eggermont, A.M.M., Chiarion-Sileni, V., Grob, J., Dummer, R., Wolchok, J.D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P.A., Richards, J.M., Lebbé, C., Ferraresi, V., Smylie, M., Weber, J.S., Maio, M., Bastholt, L., Mortier, L., Thomas, L., Tahir, S., Hauschild, A., Hassel, J.C., Hodi, F.S., Taitt, C., de Pril, V., de Schaetzen, G., Suciu, S., Testori, A.
-
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
Ascierto, P. A., Ascierto, P. A., Del Vecchio, M., Del Vecchio, M., Robert, C., Robert, C., Mackiewicz, A., Mackiewicz, A., Chiarion-Sileni, V., Chiarion-Sileni, V., Arance, A., Arance, A., Lebbé, C., Lebbé, C., Bastholt, L., Bastholt, L., Hamid, O., Hamid, O., Rutkowski, P., Rutkowski, P., McNeil, C., McNeil, C., Garbe, C., Garbe, C., Loquai, C., Loquai, C., Dreno, B., Dreno, B., Thomas, L., Thomas, L., Grob, J. J., Grob, J. J., Liszkay, G., Liszkay, G., Nyakas, M., Nyakas, M., Gutzmer, R., Gutzmer, R., Pikiel, J., Pikiel, J., Grange, F., Grange, F., Hoeller, C., Hoeller, C., Ferraresi, V., Ferraresi, V., Smylie, M., Smylie, M., Schadendorf, D., Schadendorf, D., Mortier, L., Mortier, L., Svane, I. M., Svane, I. M., Hennicken, D., Hennicken, D., Qureshi, A., Qureshi, A., Maio, M., Maio, M.
-
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
Kaufman, H. L., Russell, J. S., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Milella, M., Brownell, I., Lewis, K. D., Lorch, J. H., von Heydebreck, A., Hennessy, M., Nghiem, P.
-
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.
Hamid, O., Robert, C., Ribas, A., Hodi, F. S., Walpole, E., Daud, A., Arance, A. S., Brown, E., Hoeller, C., Mortier, L., Schachter, J., Long, J., Ebbinghaus, S., Ibrahim, N., Butler, M.
-
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Ott, P. A., Pavlick, A. C., Johnson, D. B., Hart, L. L., Infante, J. R., Luke, J. J., Lutzky, J., Rothschild, N. E., Spitler, L. E., Cowey, C. L., Alizadeh, A. R., Salama, A. K., He, Y., Hawthorne, T. R., Bagley, R. G., Zhang, J., Turner, C. D., Hamid, O.
-
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.
D'Angelo, S. P., Hunger, M., Brohl, A. S., Nghiem, P., Bhatia, S., Hamid, O., Mehnert, J. M., Terheyden, P., Shih, K. C., Brownell, I., Lebbé, C., Lewis, K. D., Linette, G. P., Milella, M., Schlichting, M., Hennessy, M. H., Bharmal, M.
-
Eruptive squamous cell carcinomas associated with BRAF-inhibitor therapy in a patient with metastatic melanoma.
Ezra, N., Hamid, O., Behroozan, D.
-
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study.
Schachter, J., Ribas, A., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C., Petrella, T. M., Hamid, O., Zhou, H., Ebbinghaus, S., Ibrahim, N., Robert, C.
-
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
Corcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., Pierobon, M., Sun, P., Cunningham, E., Little, S., Orford, K., Motwani, M., Bai, Y., Patel, K., Venook, A. P., Kopetz, S.
-
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
Hodi, F. S., Hwu, W. J., Kefford, R., Weber, J. S., Daud, A., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T. C., Joshua, A. M., Hersey, P., Dronca, R., Joseph, R., Hille, D., Xue, D., Li, X. N., Kang, S. P., Ebbinghaus, S., Perrone, A., Wolchok, J. D.
-
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
Ascierto, P. A., Minor, D., Ribas, A., Lebbe, C., O'Hagan, A., Arya, N., Guckert, M., Schadendorf, D., Kefford, R. F., Grob, J. J., Hamid, O., Amaravadi, R., Simeone, E., Wilhelm, T., Kim, K. B., Long, G. V., Martin, A. M., Mazumdar, J., Goodman, V. L., Trefzer, U.
-
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Hamid, O., Carvajal, R. D.
-
Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma.
Spitler, L. E., Boasberg, P., O'Day, S., Hamid, O., Cruickshank, S., Mesko, S., Weber, R. W.